Single-Cell Analysis Identifies Distinct Populations of Cytotoxic CD4 T Cells Linked to the Therapeutic Efficacy of Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2024 Jul 15

PMID 39006494

Authors

Xu Yang

Jianwei Wu

Longlong Fan

Binghua Chen

Shiqiang Zhang

Wenzhong Zheng

Affiliations

Soon will be listed here.

Abstract

Background: The involvement of cytotoxic CD4 T cells (CD4 CTLs) and their potential role in dictating the response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC) remains an unexplored area of research.

Methods: Utilizing single-cell RNA sequencing, we analyzed the immunophenotype and expression patterns of CD4 T lymphocyte subtypes in mRCC patients, followed by preliminary validation via multi-immunofluorescent staining. In addition, we obtained a comprehensive immunotherapy dataset encompassing single-cell RNA sequencing datasets and bulk RNA-seq cohorts from the European Genome-Phenome Archive and ArrayExpress database. Utilizing the CIBERSORTx deconvolution algorithms, we derived a signature score for CD4 CTLs from the bulk-RNA-seq datasets of the CheckMate 009/025 clinical trials.

Results: Single-cell analysis of CD4 T lymphocytes in mRCC reveals several cancer-specific states, including diverse phenotypes of regulatory T cells. Remarkably, we observe that CD4 CTLs cells constitute a substantial proportion of all CD4 T lymphocyte sub-clusters in mRCC patients, highlighting their potential significance in the disease. Furthermore, within mRCC patients, we identify two distinct cytotoxic states of CD4 T cells: CD4GZMK T cells, which exhibit a weaker cytotoxic potential, and CD4GZMB T cells, which demonstrate robust cytotoxic activity. Both regulatory T cells and CD4 CTLs originate from proliferating CD4 T cells within mRCC tissues. Intriguingly, our trajectory analysis indicates that the weakly cytotoxic CD4GZMK T cells differentiate from their more cytotoxic CD4GZMB counterparts. In comparing patients with lower CD4 CTLs levels to those with higher CD4 CTLs abundance in the CheckMate 009 and 25 immunotherapy cohorts, the latter group exhibited significantly improved OS and PFS probability.

Conclusion: Our study underscores the pivotal role that intratumoral CD4 CTLs may play in bolstering anti-tumor immunity, suggesting their potential as a promising biomarker for predicting response to ICIs in patients with mRCC.

References

Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A . Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021; 39(11):1497-1518.e11. PMC: 8599450. DOI: 10.1016/j.ccell.2021.10.001. View

Brown D, Lee S, Garcia-Hernandez M, Swain S . Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012; 86(12):6792-803. PMC: 3393557. DOI: 10.1128/JVI.07172-11. View

Giraldo N, Becht E, Pages F, Skliris G, Verkarre V, Vano Y . Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clin Cancer Res. 2015; 21(13):3031-40. DOI: 10.1158/1078-0432.CCR-14-2926. View

Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner H . Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017; 14(10):979-982. PMC: 5764547. DOI: 10.1038/nmeth.4402. View

Gulati G, Sikandar S, Wesche D, Manjunath A, Bharadwaj A, Berger M . Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020; 367(6476):405-411. PMC: 7694873. DOI: 10.1126/science.aax0249. View

Tran E, Turcotte S, Gros A, Robbins P, Lu Y, Dudley M . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344(6184):641-5. PMC: 6686185. DOI: 10.1126/science.1251102. View

Wolock S, Lopez R, Klein A . Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data. Cell Syst. 2019; 8(4):281-291.e9. PMC: 6625319. DOI: 10.1016/j.cels.2018.11.005. View

Choueiri T, Motzer R . Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017; 376(4):354-366. DOI: 10.1056/NEJMra1601333. View

Capitanio U, Montorsi F . Renal cancer. Lancet. 2015; 387(10021):894-906. DOI: 10.1016/S0140-6736(15)00046-X. View

10.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

11.

Strack R . Afterglow probes made easy. Nat Methods. 2019; 16(7):577. DOI: 10.1038/s41592-019-0483-y. View

12.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

13.

Sujino T, London M, Hoytema van Konijnenburg D, Rendon T, Buch T, Silva H . Tissue adaptation of regulatory and intraepithelial CD4⁺ T cells controls gut inflammation. Science. 2016; 352(6293):1581-6. PMC: 4968079. DOI: 10.1126/science.aaf3892. View

14.

Oh D, Fong L . Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021; 54(12):2701-2711. PMC: 8809482. DOI: 10.1016/j.immuni.2021.11.015. View

15.

Braun D, Street K, Burke K, Cookmeyer D, Denize T, Pedersen C . Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021; 39(5):632-648.e8. PMC: 8138872. DOI: 10.1016/j.ccell.2021.02.013. View

16.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

17.

Cachot A, Bilous M, Liu Y, Li X, Saillard M, Cenerenti M . Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. 2021; 7(9). PMC: 7909889. DOI: 10.1126/sciadv.abe3348. View

18.

Mucida D, Husain M, Muroi S, van Wijk F, Shinnakasu R, Naoe Y . Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol. 2013; 14(3):281-9. PMC: 3581083. DOI: 10.1038/ni.2523. View

19.

Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S . Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood. 2000; 95(7):2352-5. View

20.

Reis B, Rogoz A, Costa-Pinto F, Taniuchi I, Mucida D . Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4⁺ T cell immunity. Nat Immunol. 2013; 14(3):271-80. PMC: 3804366. DOI: 10.1038/ni.2518. View